Clinical dementia rating scale

Prednisone, 10 mg/day for 1 year, has been evaluated in 136 patients with probable Alzheimer s disease in a double-blind, randomized, placebo-controlled trial (196). There were no differences in the primary measures of efficacy (cognitive subscale of the Alzheimer Disease Assessment Scale), but those treated with prednisone had significantly greater memory impairment (Clinical Dementia sum of boxes), and agitation and hostility/suspicion (Brief Psychiatric Rating Scale). Other adverse effects in those who took prednisone were reduced bone density and a small rise in intraocular pressure. 

Acetyl-i-carnitine (4) is marketed in Italy for dementia as of this writing it is also in Phase III clinical trials in the United States and Europe. In a double-blind, placebo-controUed clinical trial over a one-year period involving 130 patients with clinically diagnosed AD, a slower rate of deterioration in 13 of the 14 outcome measures was observed in the dmg-treated group (28). Earfler smaller scale pilot studies in demented patients had also shown some improvement of various behavioral and cognitive functions (29). 

---